A carregar...
Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis
Bevacizumab (BEV), an inhibitor of vascular endothelial growth factor A, has been used for primary and recurrent malignant gliomas in Japan since June, 2013. Previous randomized controlled studies demonstrated that BEV prolonged the progression-free survival, but not the overall survival (OS) of pat...
Na minha lista:
| Publicado no: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5244831/ https://ncbi.nlm.nih.gov/pubmed/28123740 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.1086 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|